First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
Phase II, single-arm study to assess the safety and efficacy of osimertinib (80 mg, orally,
once daily) as first-line therapy in patients with EGFR mutation-positive, locally advanced
or metastatic non-small cell lung cancer (NSCLC) who have not previously treated with an
epidermal growth factor tyrosine kinase inhibitor agent.